Abstract

The aggregation of proteins into amyloid fibrils and their deposition into plaques and intracellular inclusions is the hallmark of amyloid disease. The accumulation and deposition of amyloid fibrils, collectively known as amyloidosis, is associated with many pathological conditions that can be associated with ageing, such as Alzheimer disease, Parkinson disease, type II diabetes and dialysis-related amyloidosis. However, elucidation of the atomic structure of amyloid fibrils formed from their intact protein precursors and how fibril formation relates to disease has remained elusive. Recent advances in structural biology techniques, including cryo-electron microscopy and solid-state NMR spectroscopy, have finally broken this impasse. The first near-atomic-resolution structures of amyloid fibrils formed in vitro, seeded from plaque material and analysed directly ex vivo are now available. The results reveal cross-β structures that are far more intricate than anticipated. Here, we describe these structures, highlighting their similarities and differences, and the basis for their toxicity. We discuss how amyloid structure may affect the ability of fibrils to spread to different sites in the cell and between organisms in a prion-like manner, along with their roles in disease. These molecular insights will aid in understanding the development and spread of amyloid diseases and are inspiring new strategies for therapeutic intervention.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Protein Data Bank: http://www.rcsb.org/pdb/home/home.do

References

  1. 1.

    Sipe, J. D. & Cohen, A. S. Review: History of the amyloid fibril. J. Struct. Biol. 130, 88–98 (2000).

  2. 2.

    Goedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E. & Klug, A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl Acad. Sci. USA 85, 4051–4055 (1988).

  3. 3.

    Murphy, M. P. & LeVine, I. I. I. H. Alzheimer’s disease and the β-amyloid peptide. J. Alzheimers Dis. 19, 311–323 (2010).

  4. 4.

    Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a009399 (2012).

  5. 5.

    Protein Data Bank. Yearly growth of total structures. rcbs.org http://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=total (2018).

  6. 6.

    Sipe, J. D. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelines. Amyloid 23, 209–213 (2016).

  7. 7.

    Sloane, P. D. et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. Annu. Rev. Publ. Health 23, 213–231 (2002).

  8. 8.

    Geula, C. et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 7, 827–831 (1998).

  9. 9.

    Woerner, A. C. et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science 350, 173–176 (2016).

  10. 10.

    Guo, Q. et al. In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome recruitment. Cell 172, 696–705 (2018).

  11. 11.

    Drummond, E. et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol. 133, 933–954 (2017).

  12. 12.

    Stewart, K. L. et al. Atomic details of the interactions of glycosaminoglycans with amyloid-β fibrils. J. Am. Chem. Soc. 138, 8328–8331 (2016).

  13. 13.

    Kollmer, M. et al. Electron tomography reveals the fibril structure and lipid interactions in amyloid deposits. Proc. Natl Acad. Sci. USA 113, 5604–5609 (2016).

  14. 14.

    Knowles, T. P. J. et al. Role of intermolecular forces in defining material properties of protein nanofibrils. Science 318, 1900–1903 (2007).

  15. 15.

    Smith, J. F., Knowles, T. P. J., Dobson, C. M., MacPhee, C. E. & Welland, M. E. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl Acad. Sci. USA 103, 15806–15811 (2006).

  16. 16.

    Greenwald, J., Friedmann, M. P. & Riek, R. Amyloid aggregates arise from amino acid condensations under prebiotic conditions. Angew. Chem. Int. Ed. Engl. 55, 11609–11613 (2016).

  17. 17.

    Romero, D., Aguilar, C., Losick, R. & Kolter, R. Amyloid fibers provide structural integrity to Bacillus subtilis biofilms. Proc. Natl Acad. Sci. USA 107, 2230–2234 (2010).

  18. 18.

    Taglialegna, A. et al. Staphylococcal Bap proteins build amyloid scaffold biofilm matrices in response to environmental signals. PLOS Pathog. 12, e1005711 (2016).

  19. 19.

    Lipke, P. N., Klotz, S. A., Dufrene, Y. F., Jackson, D. N. & Garcia-Sherman, M. C. Amyloid-like β-aggregates as force-sensitive switches in fungal biofilms and infections. Microbiol. Mol. Biol. Rev. 82, e00035–17 (2018).

  20. 20.

    Garvey, M., Ecroyd, H., Ray, N. J., Gerrard, J. A. & Carver, J. A. Functional amyloid protection in the eye lens: retention of alpha-crystallin molecular chaperone activity after modification into amyloid fibrils. Biomolecules 7, E67 (2017).

  21. 21.

    Biesecker, S. G., Nicastro, L. K., Wilson, R. P. & Tukel, C. The functional amyloid curli protects Escherichia coli against complement-mediated bactericidal activity. Biomolecules 8, E5 (2018).

  22. 22.

    Bajakian, T. H. et al. Metal binding properties of the N-terminus of the functional amyloid Orb2. Biomolecules 7, E57 (2017).

  23. 23.

    Audas, T. E. et al. Adaptation to stressors by systemic protein amyloidogenesis. Dev. Cell 39, 155–168 (2016).

  24. 24.

    Guyonnet, B., Egge, N. & Cornwall, G. A. Functional amyloids in the mouse sperm acrosome. Mol. Cell. Biol. 34, 2624–2634 (2014).

  25. 25.

    Fowler, D. M. et al. Functional amyloid formation within mammalian tissue. PLOS Biol. 4, e6 (2006).

  26. 26.

    Roan, N. R. et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 10, 541–550 (2011).

  27. 27.

    Gremer, L. et al. Fibril structure of amyloid-β(1–42) by cryo-electron microscopy. Science 358, 116–119 (2017).

  28. 28.

    Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature 547, 185–190 (2017).

  29. 29.

    US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02760602 (2018).

  30. 30.

    US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT00606476 (2018).

  31. 31.

    US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT01739348 (2018).

  32. 32.

    US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT00531804 (2018).

  33. 33.

    Virchow, R. Zur cellulose. Archiv. Pathol. Anat. 6, 416–426 (1854).

  34. 34.

    Friedreich, N. & Kekulé, A. Zur amyloidfrage. Virchows Arch. 16, 50–65 (1859).

  35. 35.

    Puchtler, H., Sweat, F. & Levine, M. On the binding of Congo red by amyloid. J. Histochem. Cytochem. 10, 355–364 (1962).

  36. 36.

    Benditt, E. P., Eriksen, N., Hermodson, M. A. & Ericsson, L. H. The major proteins of human and monkey amyloid substance: common properties including unusual N-terminal amino acid sequences. FEBS Lett. 19, 169–173 (1971).

  37. 37.

    Glenner, G. G., Eanes, E. D., Bladen, H. A., Terry, W. & Page, D. L. Creation of “amyloid” fibrils from Bence Jones proteins in vitro. Science 174, 712–714 (1971).

  38. 38.

    Costa, P. P., Figueria, A. S. & Bravo, F. R. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc. Natl Acad. Sci. USA 75, 4499–4503 (1978).

  39. 39.

    Astbury, W. T. & Street, A. X-ray studies of the structure of hair, wool and related fibres. I. General. Phil. Trans. R. Soc. 230, 75–101 (1932).

  40. 40.

    Hall, K. T. The Man in the Monkeynut Coat (Oxford Univ. Press, Oxford, 2014).

  41. 41.

    Geddes, A. J., Parker, K. D., Atkins, E. D. T. & Beighton, E. “Cross-β” conformation in proteins. J. Mol. Biol. 32, 343–358 (1968).

  42. 42.

    Jackson, M. & Hewitt, E. Why are functional amyloids non-toxic in humans? Biomolecules 7, E71–E73 (2017).

  43. 43.

    Hewetson, A. et al. Functional amyloids in reproduction. Biomolecules 7, E46 (2017).

  44. 44.

    Ramsook, C. B. et al. Yeast cell adhesion molecules have functional amyloid-forming sequences. Eukaryot. Cell 9, 393–404 (2010).

  45. 45.

    Romero, D. & Kolter, R. Functional amyloids in bacteria. Int. Microbiol. 17, 65–73 (2014).

  46. 46.

    Pham, C. L., Kwan, A. H. & Sunde, M. Functional amyloid: widespread in Nature, diverse in purpose. Essays Biochem. 56, 207–219 (2014).

  47. 47.

    Fowler, D. M., Koulov, A. V., Balch, W. E. & Kelly, J. W. Functional amyloid — from bacteria to humans. Trends Biochem. Sci. 32, 217–224 (2007).

  48. 48.

    Morris, K. L. & Serpell, L. C. X-Ray Fibre Diffraction Studies of Amyloid Fibrils (Humana Press, 2012).

  49. 49.

    Eanes, E. D. & Glenner, G. G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 10, 673–677 (1968).

  50. 50.

    Kirschner, D. A., Abraham, C. & Selkoe, D. J. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc. Natl Acad. Sci. USA 83, 503–507 (1986).

  51. 51.

    Sawaya, M. R. et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453–457 (2007).

  52. 52.

    Shi, D., Nannenga, B. L., Iadanza, M. G. & Gonen, T. Three-dimensional electron crystallography of protein microcrystals. eLife 2, e01345 (2013).

  53. 53.

    de la Cruz, M. J. et al. Atomic-resolution structures from fragmented protein crystals with the cryoEM method MicroED. Nat. Med. 14, 399–402 (2017).

  54. 54.

    Krotee, P. et al. Atomic structures of fibrillar segments of hIAPP suggest tightly mated beta-sheets are important for cytotoxicity. eLife 6, e19273 (2017).

  55. 55.

    Rodriguez, J. A. et al. Structure of the toxic core of alpha-synuclein from invisible crystals. Nature 525, 486–490 (2015).

  56. 56.

    Sawaya, M. R. et al. Ab initio structure determination from prion nanocrystals at atomic resolution by MicroED. Proc. Natl Acad. Sci. USA 113, 11232–11236 (2016).

  57. 57.

    Colvin, M. T. et al. High resolution structural characterization of Aβ42 amyloid fibrils by magic angle spinning NMR. J. Am. Chem. Soc. 137, 7509–7518 (2015).

  58. 58.

    Antzutkin, O. N., Leapman, R. D., Balbach, J. J. & Tycko, R. Supramolecular structural constraints on Alzheimer’s β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 41, 15436–15450 (2002).

  59. 59.

    Chan, J. C. C., Oyler, N. A., Yau, W. & Tycko, R. Parallel β -sheets and polar zippers in amyloid fibrils formed by residues 10–39 of the yeast prion protein Ure2p. Biochemistry 44, 10669–10680 (2005).

  60. 60.

    Qiang, W., Yau, W. M., Lu, J. X., Collinge, J. & Tycko, R. Structural variation in amyloid-beta fibrils from Alzheimer’s disease clinical subtypes. Nature 541, 217–221 (2017).

  61. 61.

    Qiang, W., Yau, W. M., Luo, Y., Mattson, M. P. & Tycko, R. Antiparallel beta-sheet architecture in Iowa-mutant beta-amyloid fibrils. Proc. Natl Acad. Sci. USA 109, 4443–4448 (2012).

  62. 62.

    Lührs, T. et al. 3D structure of Alzheimer’s amyloid-B(1–42) fibrils. Proc. Natl Acad. Sci. USA 102, 17342–17347 (2005).

  63. 63.

    Nelson, R. et al. Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773–778 (2005).

  64. 64.

    Vilar, M. et al. The fold of α-synuclein fibrils. Proc. Natl Acad. Sci. USA 105, 8637–8642 (2008).

  65. 65.

    Walti, M. A. et al. Atomic-resolution structure of a disease-relevant Abeta(1–42) amyloid fibril. Proc. Natl Acad. Sci. USA 113, E4976–E4984 (2016).

  66. 66.

    Wasmer, C. et al. Amyloid fibrils of the HET-s(218–289) prion from a β solenoid with a triangular hydrophobic core. Science 319, 1523–1526 (2008).

  67. 67.

    Fitzpatrick, A. W. P. et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc. Natl Acad. Sci. USA 110, 5468–5473 (2013).

  68. 68.

    Jiménez, J. et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18, 815–821 (1999).

  69. 69.

    Saibil, H. R. et al. Heritable yeast prions have a highly organized three-dimensional architecture with interfiber structures. Proc. Natl Acad. Sci. USA 109, 14906–14911 (2012).

  70. 70.

    Fändrich, M., Meinhardt, J. & Grigorieff, N. Structural polymorphism of Alzheimer Aβ and other amyloid fibrils. Prion 3, 89–93 (2009).

  71. 71.

    Sachse, C., Fändrich, M. & Grigorieff, N. Paired β-sheet structure of an Aβ(1–40) amyloid fibril revealed by electron microscopy. Proc. Natl Acad. Sci. USA 105, 7462–7466 (2008).

  72. 72.

    Sachse, C. et al. Quaternary structure of a mature amyloid fibril from Alzheimer’s Abeta(1–40) peptide. J. Mol. Biol. 362, 347–354 (2006).

  73. 73.

    Kirschner, D. A. et al. In vitro amyloid fibril formation by synthetic peptides corresponding to the amino terminus of apoSAA isoforms from amyloid-susceptible and amyloid-resistant mice. J. Struct. Biol. 124, 88–98 (1998).

  74. 74.

    Castaño, E. M. et al. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer’s disease β-protein. Biochem. Biophys. Res. Commun. 141, 782–789 (1986).

  75. 75.

    Aggeli, A. et al. Responsive gels formed by the spontanious self-assembly of peptides into polymeric β-sheet tapes. Nature 386, 259–262 (1997).

  76. 76.

    Colletier, J. P. et al. Molecular basis for amyloid-beta polymorphism. Proc. Natl Acad. Sci. USA 108, 16938–16943 (2011).

  77. 77.

    Gosal, W. S. et al. Competing pathways determine fibril morphology in the self-assembly of beta2-microglobulin into amyloid. J. Mol. Biol. 351, 850–864 (2005).

  78. 78.

    Booth, D. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 797–793 (1997).

  79. 79.

    Hecht, M. H., Das, A., Go, A., Bradley, L. H. & Wei, Y. De novo proteins from designed combinatorial libraries. Protein. Sci. 13, 1711–1723 (2004).

  80. 80.

    Kühlbrandt, W. The resolution revolution. Science 343, 1443–1444 (2014).

  81. 81.

    Pinotsi, D. et al. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano. Lett. 14, 339–345 (2014).

  82. 82.

    Kaminski Schierle, G. S. et al. In situ measurements of the formation and morphology of intracellular beta-amyloid fibrils by super-resolution fluorescence imaging. J. Am. Chem. Soc. 133, 12902–12905 (2011).

  83. 83.

    Han, S. et al. Amyloid plaque structure and cell surface interactions of beta-amyloid fibrils revealed by electron tomography. Sci. Rep. 7, 43577 (2017).

  84. 84.

    Bauerlein, F. J. B. et al. In situ architecture and cellular interactions of polyQ inclusions. Cell 171, 179–187 (2017).

  85. 85.

    Tang, M., Comellas, G. & Rienstra, C. M. Advanced solid-state NMR approaches for structure determination of membrane proteins and amyloid fibrils. Acc. Chem. Res. 46, 2080–2088 (2013).

  86. 86.

    Alzheimer, A. Über einen eigenartigen schweren Erkrankungsprozeβ der Hirnrincle. Neurol. Central 25, 1134 (1906).

  87. 87.

    Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 641, 46–48 (1907).

  88. 88.

    Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 86, 27–68 (2006).

  89. 89.

    Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188–1203 (2012).

  90. 90.

    Westermark, P. et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12, 1–4 (2005).

  91. 91.

    Vassar, R., Bennett, B. D., Babu-Khan, S. & Kahn, S. β-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).

  92. 92.

    Prusiner, S. B., Bowman, K. A., Bendheim, P. E. & Glenner, G. G. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35, 349–358 (1983).

  93. 93.

    Warby, S. C. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am. J. Hum. Genet. 84, 351–366 (2009).

  94. 94.

    Chartier-Harlin, M.-C. et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364, 1167–1169 (2004).

  95. 95.

    Valentine, J. S., Doucette, P. A. & Zittin Potter, S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu. Rev. Biochem. 74, 563–593 (2005).

  96. 96.

    Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 91, 795–826 (2011).

  97. 97.

    Sanchorawala, V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin. J. Am. Soc. Nephrol. 1, 1331–1335 (2006).

  98. 98.

    Koch, K. M. Dialysis-related amyloidosis. Kidney Int. 41, 1416–1429 (1992).

  99. 99.

    Li, X., Song, D. & Leng, S. X. Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin. Interv. Aging 10, 549–560 (2015).

  100. 100.

    Uéda, K. et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282–11286 (1993).

  101. 101.

    Maresova, P., Klimova, B., Novotny, M. & Kuca, K. Alzheimer’s and Parkinson’s diseases: Expected economic Impact on Europe-A call for a uniform European strategy. J. Alzheimers Dis. 54, 1123–1133 (2016).

  102. 102.

    Li, J., Uversky, V. N. & Fink, A. L. Effect of familial Parkinson’s disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604–11613 (2001).

  103. 103.

    Krone, M. G. et al. Effects of familial Alzheimer’s disease mutations on the folding nucleation of the amyloid beta-protein. J. Mol. Biol. 381, 221–228 (2008).

  104. 104.

    Mangione, P. P. et al. Structure, folding dynamics, and amyloidogenesis of D76N beta2-microglobulin: roles of shear flow, hydrophobic surfaces, and alpha-crystallin. J. Biol. Chem. 288, 30917–30930 (2013).

  105. 105.

    Fan, H.-C. et al. Polyglutamine (PolyQ) diseases: genetics to treatments. Cell Transplant. 23, 441–458 (2014).

  106. 106.

    Scheuermann, T. et al. Trinucleotide expansions leading to an extended poly-L-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation. Protein Sci. 12, 2685–2692 (2003).

  107. 107.

    Brais, B. et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 18, 164–167 (1998).

  108. 108.

    Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268 (2011).

  109. 109.

    DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256 (2011).

  110. 110.

    Budworth, H. & McMurray, C. T. A brief history of triplet repeat diseases. Methods. Mol. Biol. 1010, 3–17 (2013).

  111. 111.

    Wiltfang, J. et al. Amyloid beta peptide ratio 42/40 but not Aβ 42 correlates with phospho-Tau in patients with low- and high-CSF Aβ 40 load. J. Neurochem. 101, 1053–1059 (2007).

  112. 112.

    Ramella, N. A. et al. Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. PLOS One 6, e22532 (2011).

  113. 113.

    Chiti, F. et al. A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J. Biol. Chem. 276, 46714–46721 (2001).

  114. 114.

    Eichner, T. & Radford, S. E. A generic mechanism of β2-microglobulin amyloid assembly at neutral pH involving a specific proline switch. J. Mol. Biol. 386, 1312–1326 (2009).

  115. 115.

    Byers, B. et al. SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLOS One 6, e26159 (2011).

  116. 116.

    Lott, I. T. & Head, E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol. Aging 26, 383–389 (2005).

  117. 117.

    Scarpioni, R. et al. Dialysis-related amyloidosis: challenges and solutions. Int. J. Nephrol. Renovasc. Dis. 9, 319–328 (2016).

  118. 118.

    Banani, S. F., Lee, H. O., Hyman, A. A. & Rosen, M. K. Biomolecular condensates: organizers of cellular biochemistry. Nat. Rev. Mol. Cell Biol. 18, 285–298 (2017).

  119. 119.

    Wegmann, S. et al. Tau protein liquid-liquid phase separation can initiate tau aggregation. EMBO J. 37, e98049 (2018).

  120. 120.

    Xiang, S. et al. The LC domain of hnRNPA2 adopts similar conformations in hydrogel polymers, liquid-like droplets, and nuclei. Cell 163, 829–839 (2015).

  121. 121.

    Olzscha, H. et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67–78 (2011).

  122. 122.

    Kovacs, G. G. & Budka, H. Prion diseases: from protein to cell pathology. Am. J. Pathol. 172, 555–565 (2008).

  123. 123.

    Aguzzi, A. & Calella, A. M. Prions: protein aggregation and infectious diseases. Physiol. Rev. 89, 1105–1150 (2009).

  124. 124.

    Aguzzi, A., Baumann, F. & Bremer, J. The prion’s elusive reason for being. Annu. Rev. Neurosci. 31, 439–477 (2008).

  125. 125.

    Botsios, S. & Manuelidis, L. CJD and scrapie require agent-associated nucleic acids for infection. J. Cell. Biochem. 117, 1947–1958 (2016).

  126. 126.

    Wadsworth, J. D. F. et al. Kuru prions and sporadic Creutzfeldt–Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc. Natl Acad. Sci. USA 105, 3885–3890 (2008).

  127. 127.

    Cobb, N. J. & Surewicz, W. K. Prion diseases and their biochemical mechanisms. Biochemistry 48, 2574–2585 (2009).

  128. 128.

    Wadsworth, J. D. F. et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 171–180 (2001).

  129. 129.

    Masuda-Suzukake, M. et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128–1138 (2013).

  130. 130.

    Walker, L. C., Schelle, J. & Jucker, M. The prion-like properties of amyloid-β assemblies: implications for Alzheimer’s disease. Cold Spring Harb. Perspect. Med. 6, a024398 (2016).

  131. 131.

    An, L., Fitzpatrick, D. & Harrison, P. M. Emergence and evolution of yeast prion and prion-like proteins. BMC Evol. Biol. 16, 24 (2016).

  132. 132.

    Alberti, S., Halfmann, R., King, O., Kapila, A. & Lindquist, S. A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137, 146–158 (2009).

  133. 133.

    Sponarova, J., Nystrom, S. N. & Westermark, G. T. AA-amyloidosis can be transferred by peripheral blood monocytes. PLOS One 3, e3308 (2008).

  134. 134.

    Solomon, A. et al. Amyloidogenic potential of foie gras. Proc. Nat. Acad. Sci. USA 104, 10998–11001 (2007).

  135. 135.

    Knowles, T. P., Vendruscolo, M. & Dobson, C. M. The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell. Biol. 15, 384–396 (2014).

  136. 136.

    Ferrone, F. Analysis of protein aggregation kinetics. Methods Enzymol. 309, 256–274 (1999).

  137. 137.

    Sicorello, A. et al. Agitation and high ionic strength induce amyloidogenesis of a folded PDZ domain in native conditions. Biophys. J. 96, 2289–2298 (2009).

  138. 138.

    Glabe, C. G. & Kayed, R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74–S78 (2006).

  139. 139.

    Glabe, C. G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570–575 (2006).

  140. 140.

    Meisl, G. et al. Molecular mechanisms of protein aggregation from global fitting of kinetic models. Nat. Protoc. 11, 252–272 (2016).

  141. 141.

    Linse, S. Monomer-dependent secondary nucleation in amyloid formation. Biophys. Rev. 9, 329–338 (2017).

  142. 142.

    Oosawa, F. & Asakura, S. Thermodynamics of the Polymerization of Protein (Academic Press, 1975).

  143. 143.

    Eaton, W. A. & Hofrichter, J. Hemoglobin S gelation and sickle cell disease. Blood 70, 1245–1266 (1987).

  144. 144.

    Xue, W. F., Homans, S. W. & Radford, S. E. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc. Natl Acad. Sci. USA 105, 8926–8931 (2008).

  145. 145.

    Cohen, S. I. A. et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758–9763 (2013).

  146. 146.

    LeVine, H.r. Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein. Sci. 2, 404–410 (1993).

  147. 147.

    Galvagnion, C. et al. Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229–234 (2015).

  148. 148.

    Buell, A. K. et al. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation. Proc. Natl Acad. Sci. USA 27, 7671–7676 (2014).

  149. 149.

    Arosio, P. et al. Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. Nat. Commun. 7, 10948 (2016).

  150. 150.

    Habchi, J. et al. Systematic development of small molecules to inhibit specific microscopic steps of Abeta42 aggregation in Alzheimer’s disease. Proc. Natl Acad. Sci. USA 114, E200–E208 (2017).

  151. 151.

    Jackson, M. P. & Hewitt, E. W. Cellular proteostasis: degradation of misfolded proteins by lysosomes. Essays Biochem. 60, 173–180 (2016).

  152. 152.

    Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects of protein folding and quality control. Science 353, aac4354 (2016).

  153. 153.

    Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M. & Hartl, F. U. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 82, 323–355 (2013).

  154. 154.

    Salminen, A. et al. Impaired autophagy and APP processing in Alzheimer’s disease: the potential role of Beclin 1 interactome. Prog. Neurobiol. 106–107, 33–54 (2013).

  155. 155.

    Winklhofer, K. F. & Haass, C. Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 1802, 29–44 (2010).

  156. 156.

    Uttara, B., Singh, A. V., Zamboni, P. & Mahajan, R. T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7, 65–74 (2009).

  157. 157.

    McLaurin, J. & Chakrabartty, A. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J. Biol. Chem. 25, 26482–26489 (1996).

  158. 158.

    Goodchild, S. C. et al. β2-Microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pH. PLOS One 9, e104492 (2014).

  159. 159.

    Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).

  160. 160.

    Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W. & Buxbaum, J. N. Tissue damage in the amyloidoses: transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc. Natl Acad. Sci. USA 101, 2817–2822 (2004).

  161. 161.

    Baglioni, S. et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 26, 8160–8167 (2006).

  162. 162.

    Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507–511 (2002).

  163. 163.

    Simoneau, S. et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLOS Pathog. 3, e125 (2007).

  164. 164.

    Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194–4199 (2011).

  165. 165.

    Serra-Batiste, M. et al. Aβ42 assembles into specific beta-barrel pore-forming oligomers in membrane-mimicking environments. Proc. Natl Acad. Sci. USA 113, 10866–10871 (2016).

  166. 166.

    Evangelisti, E. et al. Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. Sci. Rep. 6, 32721 (2016).

  167. 167.

    Pfefferkorn, C. M., Jiang, Z. & Lee, J. C. Biophysics of α-synuclein membrane interactions. Biochim. Biophys. Acta 1818, 162–171 (2012).

  168. 168.

    Lashuel, H. A. et al. α-Synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089–1102 (2002).

  169. 169.

    Lesné, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).

  170. 170.

    Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842 (2008).

  171. 171.

    Fusco, G. et al. Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers. Science 358, 1440–1443 (2017).

  172. 172.

    Tosatto, L. et al. Single-molecule FRET studies on α-synuclein oligomerization of Parkinson’s disease genetically related mutants. Sci. Rep. 5, 16696 (2015).

  173. 173.

    Chiti, F. & Dobson, C. M. Amyloid formation by globular proteins under native conditions. Nat. Chem. Biol. 5, 15–22 (2009).

  174. 174.

    Tsigelny, I. F. et al. Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 279, 1000–1013 (2012).

  175. 175.

    Young, L. M., Cao, P., Raleigh, D. P., Ashcroft, A. E. & Radford, S. E. Ion mobility spectrometry-mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J. Am. Chem. Soc. 136, 660–670 (2014).

  176. 176.

    Young, L. M., Tu, L. H., Raleigh, D. P., Ashcroft, A. E. & Radford, S. E. Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers. Chem. Sci. 8, 5030–5040 (2017).

  177. 177.

    Tipping, K. W., van Oosten-Hawle, P., Hewitt, E. W. & Radford, S. E. Amyloid fibres: inert end-stage aggregates or key players in disease? Trends Biochem. Sci. 40, 719–727 (2015).

  178. 178.

    Milanesi, L. et al. Direct three-dimensional visualization of membrane disruption by amyloid fibrils. Proc. Natl Acad. Sci. USA 109, 20455–20460 (2012).

  179. 179.

    Phelan, M. M., Caamaño-Gutiérrez, E., Gant, M. S., Grosman, R. X. & Madine, J. Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein. Metabolomics 13, 151 (2017).

  180. 180.

    Gharibyan, A. L. et al. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 365, 1337–1349 (2007).

  181. 181.

    Grudzielanek, S. et al. Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways. J. Mol. Biol. 370, 372–384 (2007).

  182. 182.

    Novitskaya, V., Bocharova, O. V., Bronstein, I. & Baskakov, I. V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281, 13828–13836 (2006).

  183. 183.

    Berthelot, K., Ta, H. P., Géan, J., Lecomte, S. & Cullin, C. In vivo and in vitro analyses of toxic mutants of HET-S: FTIR antiparallel signature correlates with amyloid toxicity. J. Mol. Biol. 412, 137–152 (2011).

  184. 184.

    Lee, Y. J., Savtchenko, R., Ostapchenko, V. G., Makarava, N. & Baskakov, I. V. Molecular structure of amyloid fibrils controls the relationship between fibrillar size and toxicity. PLOS One 6, e20244 (2011).

  185. 185.

    Mossuto, M. F. et al. Disulfide bonds reduce the toxicity of the amyloid fibrils formed by an extracellular protein. Angew. Chem. Int. Ed. Engl. 50, 7048–7051 (2011).

  186. 186.

    Makarava, N. et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol. 119, 177–187 (2010).

  187. 187.

    Qiang, W., Kelley, K. & Tycko, R. Polymorph-specific kinetics and thermodynamics of beta-amyloid fibril growth. J. Am. Chem. Soc. 135, 6860–6871 (2013).

  188. 188.

    Stewart, K. L., Hughes, E., Yates, E. A., Middleton, D. A. & Radford, S. E. Molecular origins of the compatibility between glycosaminoglycans and Aβ40 amyloid fibrils. J. Mol. Biol. 429, 2449–2462 (2017).

  189. 189.

    Cohen, M. L. et al. Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-beta. Brain 138, 1009–1022 (2015).

  190. 190.

    Tipping, K. W. et al. pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers. Proc. Natl Acad. Sci. USA 112, 5691–5696 (2015).

  191. 191.

    Serra-Vidal, B. et al. Hydrogen/deuterium exchange-protected oligomers populated during Abeta fibril formation correlate with neuronal cell death. ACS Chem. Biol. 9, 2678–2685 (2014).

  192. 192.

    Pilla, E., Schneider, K. & Bertolotti, A. Coping with protein quality control failure. Annu. Rev. Cell. Dev. Biol. 33, 439–465 (2017).

  193. 193.

    Schneider, K. & Bertolotti, A. Surviving protein quality control catastrophes—from cells to organisms. J. Cell Sci. 128, 3861–3869 (2015).

  194. 194.

    Walther, D. M. et al. Widespread proteome remodeling and aggregation in aging C. elegans. Cell 161, 919–932 (2015).

  195. 195.

    Ciryam, P., Kundra, R., Morimoto, R. I., Dobson, C. M. & Vendruscolo, M. Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases. Trends Pharmacol. Sci. 36, 72–77 (2015).

  196. 196.

    Kundra, R., Ciryam, P., Morimoto, R. I., Dobson, C. M. & Vendruscolo, M. Protein homeostasis of a metastable subproteome associated with Alzheimer’s disease. Proc. Natl Acad. Sci. USA 114, E5703–E5711 (2017).

  197. 197.

    Bonar, L., Cohen, A. S. & Skinner, M. M. Characterization of the amyloid fibril as a cross-beta protein. Proc. Soc. Exp. Biol. Med. 131, 1373–1375 (1969).

  198. 198.

    Blake, C. & Serpell, L. C. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 4, 989–998 (1996).

  199. 199.

    Serpell, L. C. & Smith, J. M. Direct visualisation of the β-sheet structure of synthetic Alzheimer’s amyloid. J. Mol. Biol. 299, 225–231 (2000).

  200. 200.

    Jahn, T. R., Tennent, G. A. & Radford, S. E. A common beta-sheet architecture underlies in vitro and in vivo β-2-microglobulin amyloid fibrils. J. Biol. Chem. 283, 17279–17286 (2008).

  201. 201.

    Zandomeneghi, G., Krebs, M. R., McCammon, M. G. & Fandrich, M. FTIR reveals structural differences between native β-sheet proteins and amyloid fibrils. Protein. Sci. 13, 3314–3321 (2004).

  202. 202.

    Sarroukh, R., Goormaghtigh, E., Ruysschaert, J. M. & Raussens, V. ATR-FTIR: a “rejuvenated” tool to investigate amyloid proteins. Biochim. Biophys. Acta 1828, 2328–2338 (2013).

  203. 203.

    Adler-Abramovich, L. et al. Phenylalanine assembly into toxic fibrils suggests amyloid etiology in phenylketonuria. Nat. Chem. Biol. 8, 701–706 (2012).

  204. 204.

    Julien, O. et al. Unraveling the mechanism of cell death induced by chemical fibrils. Nat. Chem. Biol. 10, 969–976 (2014).

  205. 205.

    Lazar, K. L., Miller-Auer, H., Getz, G. S., Orgel, J. P. R. O. & Meredith, S. C. Helix-turn-helix peptides that form alpha-helical fibrils: turn sequences drive fibril structure. Biochemistry 44, 12681–12689 (2005).

  206. 206.

    Tayeb-Fligelman, E. et al. The cytotoxic Staphylococcus aureus PSMa3 reveals a cross-α amyloid-like fibril. Science 355, 831–833 (2017).

  207. 207.

    Sangwan, S. et al. Atomic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 114, 8770–8775 (2017).

  208. 208.

    Laganowsky, A. et al. Atomic view of a toxic amyloid small oligomer. Science 335, 1228–1231 (2012).

  209. 209.

    Shirahama, T. & Cohen, A. S. Structure of amyloid fibrils after negative staining and high-resolution electron microscopy. Nature 206, 737–738 (1965).

  210. 210.

    Tattum, M. H. et al. Elongated oligomers assemble into mammalian PrP amyloid fibrils. J. Mol. Biol. 357, 975–985 (2006).

  211. 211.

    White, H. E. et al. Globular tetramers of β(2)-microglobulin assemble into elaborate amyloid fibrils. J. Mol. Biol. 389, 48–57 (2009).

  212. 212.

    Paravastua, A. K., Leapman, R. D., Yau, W. & Tycko, R. Molecular structural basis for polymorphism in Alzheimer’s β-amyloid fibrils. Proc. Natl Acad. Sci. USA 105, 18349–18354 (2008).

  213. 213.

    Lu, J. X. et al. Molecular structure of beta-amyloid fibrils in Alzheimer’s disease brain tissue. Cell 154, 1257–1268 (2013).

  214. 214.

    Kajava, A. V., Baxa, U., Wickner, R. B. & Steven, A. C. A model for Ure2p prion filaments and other amyloids: the parallel superpleated beta-structure. Proc. Natl Acad. Sci. USA 101, 7885–7890 (2004).

  215. 215.

    Kajava, A. V., Aebi, U. & Steven, A. C. The parallel superpleated β-structure as a model for amyloid fibrils of human amylin. J. Mol. Biol. 348, 247–252 (2005).

  216. 216.

    Tuttle, M. D. et al. Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nat. Struct. Mol. Biol. 23, 409–415 (2016).

  217. 217.

    Marshall, K. E. et al. Characterizing the assembly of the Sup35 yeast prion fragment, GNNQQNY: structural changes accompany a fiber-to-crystal switch. Biophys. J. 98, 330–338 (2010).

  218. 218.

    Reynolds, N. P. et al. Competition between crystal and fibril formation in molecular mutations of amyloidogenic peptides. Nat. Commun. 8, 1338 (2017).

  219. 219.

    Saracino, G. A., Villa, A., Moro, G., Cosentino, U. & Salmona, M. Spontaneous beta-helical fold in prion protein: the case of PrP(82–146). Proteins 75, 964–976 (2009).

  220. 220.

    Kajava, A. V. & Steven, A. C. β-rolls, β-helices, and other β-solenoid proteins. Adv. Protein Chem. 73, 55–96 (2006).

  221. 221.

    Peng, Z., Peralta, M. D. R. & Toney, M. D. Extraordinarily stable amyloid fibrils engineered from structurally defined beta-solenoid proteins. Biochemistry 56, 6041–6050 (2017).

  222. 222.

    Wolfram, F. et al. Catalytic mechanism and mode of action of the periplasmic alginate epimerase AlgG. J. Biol. Chem. 289, 6006–6019 (2014).

  223. 223.

    Leinala, E. K., Davies, P. L. & Jia, Z. Crystal structure of beta-helical antifreeze protein points to a general ice binding model. Structure 10, 619–627 (2002).

  224. 224.

    Muller, J. J. et al. An intersubunit active site between supercoiled parallel beta helices in the trimeric tailspike endorhamnosidase of Shigella flexneri Phage Sf6. Structure 16, 766–775 (2008).

  225. 225.

    Kajava, A. V., Baxa, U. & Steven, A. C. Beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils. FASEB J. 24, 1311–1319 (2010).

  226. 226.

    Ritter, C. et al. Correlation of structural elements and infectivity of the HET-s prion. Nature 435, 844–848 (2005).

  227. 227.

    Bousset, L. et al. Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575 (2013).

  228. 228.

    Goldsbury, C. S. et al. Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119, 17–21 (1997).

  229. 229.

    Jiménez, J. et al. The protofilament structure of insulin amyloid fibrils. Proc. Natl Acad. Sci. USA 99, 9196–9201 (2002).

  230. 230.

    Dearborn, A. D. et al. Alpha-synuclein amyloid fibrils with two entwined, asymmetrically associated protofibrils. J. Biol. Chem. 291, 2310–2318 (2016).

  231. 231.

    Andersen, C. B. et al. Glucagon fibril polymorphism reflects differences in protofilament backbone structure. J. Mol. Biol. 397, 932–946 (2010).

  232. 232.

    Xiao, Y. et al. Aβ(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat. Struct. Mol. Biol. 22, 499–505 (2015).

  233. 233.

    Chen, B., Thurber, K. R., Shewmaker, F., Wickner, R. B. & Tycko, R. Measurement of amyloid fibril mass-per-length by tilted-beam transmission electron microscopy. Proc. Natl Acad. Sci. USA 106, 14339–14344 (2009).

  234. 234.

    Doussineau, T. et al. Mass determination of entire amyloid fibrils by using mass spectrometry. Angew. Chem. Int. Ed. Engl. 55, 2340–2344 (2016).

  235. 235.

    Crick, F. H. C. & Rich, A. Structure of polyglyciene II. Nature 176, 780–781 (1955).

  236. 236.

    Lee, M. et al. Zinc-binding structure of a catalytic amyloid from solid-state NMR. Proc. Natl Acad. Sci. USA 114, 6191–6196 (2017).

  237. 237.

    Viles, J. H. Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer’s, Parkinson’s and prion diseases. Coords. Chem. Rev. 256, 2271–2284 (2012).

  238. 238.

    Gath, J. et al. Yet another polymorph of α-synuclein: solid-state sequential assignments. Biomol. NMR Assign. 8, 395–404 (2014).

  239. 239.

    Gath, J. et al. Unlike twins: an NMR comparison of two α-synuclein polymorphs featuring different toxicity. PLOS One 9, e90659 (2014).

  240. 240.

    Anfinsen, C. Principals that govern the folding of protein chains. Science 181, 223–230 (1973).

  241. 241.

    Sidhu, A., Segers-Nolten, I., Raussens, V., Claessens, M. M. & Subramaniam, V. Distinct mechanisms determine α-synuclein fibril morphology during growth and maturation. ACS Chem. Neurosci. 8, 538–547 (2017).

  242. 242.

    Eichner, T. & Radford, S. E. A diversity of assembly mechanisms of a generic amyloid fold. Mol. Cell 43, 8–18 (2011).

  243. 243.

    Weissmann, C. & Flechsig, E. PrP knock-out and PrP transgenic mice in prion research. Br. Med. Bull. 66, 43–60 (2003).

  244. 244.

    Geschwind, M. D. Prion diseases. Continuum (Minneap. Minn.) 21, 1612–1638 (2015).

  245. 245.

    Kitazawa, M., Medeiros, R. & LaFerla, F. M. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr. Pharm. Des. 18, 1131–1147 (2012).

  246. 246.

    Khalaf, O. et al. The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity. J. Biol. Chem. 289, 21856–21876 (2014).

  247. 247.

    Appel-Cresswell, S. et al. Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov. Disord. 28, 811–813 (2013).

  248. 248.

    Lesage, S. et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73, 459–471 (2013).

  249. 249.

    Nielsen, S. B. et al. Wildtype and A30P mutant α-synuclein form different fibril structures. PLOS One 8, e67713 (2013).

  250. 250.

    Petrucci, S., Ginevrino, M. & Valente, E. M. Phenotypic spectrum of α-synuclein mutations: New insights from patients and cellular models. Parkinsonism Relat. Disord. 22 (Suppl. 1), S16–S20 (2016).

  251. 251.

    Schutz, A. K. et al. Atomic-resolution three-dimensional structure of amyloid beta fibrils bearing the Osaka mutation. Angew. Chem. Int. Ed. Engl. 54, 331–335 (2015).

  252. 252.

    Andresen, J. M. et al. The relationship between CAG repeat length and age of onset differs for Huntington’s disease patients with juvenile onset or adult onset. Ann. Hum. Genet. 71, 295–301 (2007).

  253. 253.

    Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrils. Science 307, 262–265 (2005).

  254. 254.

    Stöhr, j. et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions. Proc. Natl Acad. Sci. USA 109, 11025–11030 (2012).

  255. 255.

    Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781–1784 (2006).

  256. 256.

    Liu, J. et al. Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. Sci. Rep. 6, 33079 (2016).

  257. 257.

    Nyström, S. et al. Evidence for age-dependent in vivo conformational rearrangement within Aβ amyloid deposits. ACS Chem. Biol 8, 1128–1133 (2013).

  258. 258.

    Perez-Nievas, B. G. et al. Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology. Brain 136, 2510–2526 (2013).

  259. 259.

    Elman, J. A. et al. Neural compensation in older people with brain amyloid-beta deposition. Nat. Neurosci. 17, 1316–1318 (2014).

  260. 260.

    Strømland, Ø., Jakubec, M., Furse, S. & Halskau, Ø. Detection of misfolded protein aggregates from a clinical perspective. J. Clin. Transl Res. 2, 11–26 (2016).

  261. 261.

    Bulawa, C. E. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA 109, 9629–9634 (2012).

  262. 262.

    Ludtmann, M. H. et al. Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J. Neurosci. 36, 10510–10521 (2016).

  263. 263.

    Pearson, H. A. & Peers, C. Physiological roles for amyloid beta peptides. J. Physiol. 575, 5–10 (2006).

  264. 264.

    Barucker, C. et al. Abeta42-oligomer interacting peptide (AIP) neutralizes toxic amyloid-beta42 species and protects synaptic structure and function. Sci. Rep. 5, 15410 (2015).

  265. 265.

    Du, W. J. et al. Brazilin inhibits amyloid beta-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Sci. Rep. 5, 7992 (2015).

  266. 266.

    Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid-beta receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174–3183 (2016).

  267. 267.

    Mao, X. et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374 (2016).

  268. 268.

    Verma, M., Vats, A. & Taneja, V. Toxic species in amyloid disorders: Oligomers or mature fibrils. Ann. Indian Acad. Neurol. 18, 138–145 (2015).

  269. 269.

    Berry, D. B. et al. Drug resistance confounding prion therapeutics. Proc. Natl Acad. Sci. USA Proc. Natl Acad. Sci. USA 110, E4160–E4169 (2013).

  270. 270.

    Li, J., Browning, S., Mahal, S. P., Oelschlegel, A. M. & Weissmann, C. Darwinian evolution of prions in cell culture. Science 327, 869–872 (2010).

  271. 271.

    Oelschlegel, A. M. & Weissmann, C. Acquisition of drug resistance and dependence by prions. PLOS Pathog. 9, e1003158 (2013).

  272. 272.

    Seidler, P. M. et al. Structure-based inhibitors of tau aggregation. Nat. Chem. 10, 170–176 (2018).

  273. 273.

    Sievers, S. A. et al. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 475, 96–100 (2011).

  274. 274.

    Jiang, L. et al. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. eLife 2, e00857 (2013).

  275. 275.

    Kad, N. M. et al. Hierarchical assembly of β2-microglobulin amyloid in vitro revealed by atomic force microscopy. J. Mol. Biol. 330, 785–797 (2003).

  276. 276.

    Watanabe-Nakayama, T. et al. High-speed atomic force microscopy reveals structural dynamics of amyloid beta1-42 aggregates. Proc. Natl Acad. Sci. USA 113, 5835–5840 (2016).

  277. 277.

    Silvers, R. et al. Aggregation and fibril structure of AβMO1-42 and Aβ1-42. Biochemistry 56, 4850–4859 (2017).

  278. 278.

    Colvin, M. T. et al. Atomic resolution structure of monomorphic Aβ42 amyloid fibrils. J. Am. Chem. Soc. 138, 9663–9674 (2016).

  279. 279.

    Schütz, A. K. et al. Binding of polythiophenes to amyloids: structural mapping of the pharmacophore. ACS Chem. Neurosci. 9, 475–481 (2017).

  280. 280.

    Ries, J. et al. Superresolution imaging of amyloid fibrils with binding-activated probes. ACS Chem. Neurosci. 4, 1057–1061 (2013).

  281. 281.

    Choi, J. H., May, B. C., Wille, H. & Cohen, F. E. Molecular modeling of the misfolded insulin subunit and amyloid fibril. Biophys. J. 97, 3187–3195 (2009).

  282. 282.

    Ladner, C. L. et al. Stacked sets of parallel, in-register beta-strands of beta2-microglobulin in amyloid fibrils revealed by site-directed spin labeling and chemical labeling. J. Biol. Chem. 285, 17137–17147 (2010).

  283. 283.

    Zhang, Y. et al. Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid beta (Abeta) peptide aggregation. Proc. Natl Acad. Sci. USA 110, 14604–14609 (2013).

  284. 284.

    Der-Sarkissian, A., Jao, C. C., Chen, J. & Langen, R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278, 37530–37535 (2003).

  285. 285.

    Varkey, J. & Langen, R. Membrane remodeling by amyloidogenic and non-amyloidogenic proteins studied by EPR. J. Magn. Reson. 280, 127–139 (2017).

  286. 286.

    Cohen, A. S. & Calkins, E. Electron microscopic observations on a fiberous component in amyloid of diverse origins. Nature 183, 1202–1203 (1959).

  287. 287.

    Cohen, A. S. & Shirahama, T. High resolution electron microscopic analysis of the amyloid fibril. J. Cell Bio. 33, 679 (1967).

  288. 288.

    Astbury, W. T. X-ray studies of protein structure. Cold Spring Harb. Symp. Quant. Biol. 2, 15–27 (1934).

  289. 289.

    Jimenez, J. L., Tennent, G., Pepys, M. & Saibil, H. R. Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy. J. Mol. Biol. 311, 241–247 (2001).

  290. 290.

    Schaffer, J. et al. Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients. Kidney Int. 58, 873–880 (2000).

  291. 291.

    Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A. & Franklin, E. C. The characterization of soluble amyloid prepared in water. J. Clin. Invest. 47, 924–933 (1968).

  292. 292.

    Fändrich, M. & Dobson, C. M. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21, 5682–5690 (2002).

  293. 293.

    Sikorski, P. & Atkins, E. New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 6, 425–432 (2005).

  294. 294.

    Ranson, N., Stromer, T., Bousset, L., Melki, R. & Serpell, L. C. Insights into the architecture of the Ure2p yeast protein assemblies from helical twisted fibrils. Protein Sci. 15, 2481–2487 (2006).

  295. 295.

    Graeber, M. B., Kösel, S., Grasbon-Frodl, E., Möller, H. J. & Mehraein, P. Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics 1, 223–228 (1998).

  296. 296.

    Nicoll, A. J. et al. Amyloid-beta nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 4, 2416 (2013).

  297. 297.

    Martins, I. C. et al. Lipids revert inert Aβ amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27, 224–233 (2008).

  298. 298.

    Jakhria, T. et al. beta2-microglobulin amyloid fibrils are nanoparticles that disrupt lysosomal membrane protein trafficking and inhibit protein degradation by lysosomes. J. Biol. Chem. 289, 35781–35794 (2014).

  299. 299.

    Fujioka, S. et al. Update on novel familial forms of Parkinson’s disease and multiple system atrophy. Parkinsonism Relat. Disord. 20, S29–S34 (2014).

  300. 300.

    Pagano, G., Ferrara, N., Brooks, D. J. & Pavese, N. Age at onset and Parkinson disease phenotype. Neurology 86, 1400–1407 (2016).

Download references

Acknowledgements

The authors thank members of their laboratories and their colleagues for many helpful discussions while preparing this Review. M.G.I., M.P.J., E.W.H., N.A.R and S.E.R. acknowledge funding from the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007-2013) ERC grant agreement no. 322408 and from the Wellcome Trust (092896MA and 204963).

Author information

Author notes

  1. These authors contributed equally: Matthew G. Iadanza, Matthew P. Jackson.

Affiliations

  1. Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK

    • Matthew G. Iadanza
    • , Matthew P. Jackson
    • , Eric W. Hewitt
    • , Neil A. Ranson
    •  & Sheena E. Radford

Authors

  1. Search for Matthew G. Iadanza in:

  2. Search for Matthew P. Jackson in:

  3. Search for Eric W. Hewitt in:

  4. Search for Neil A. Ranson in:

  5. Search for Sheena E. Radford in:

Contributions

All authors wrote the manuscript.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Sheena E. Radford.

Glossary

Amyloid

Fibrils formed from proteins, marked by a characteristic cross-β organization with an ~4.7–4.8 Å repeat running down the fibril axis.

Cross-β

The structural motif consisting of β-strands organized perpendicular to the axis of a fibril and stabilized by inter-strand hydrogen bonds and dry steric zipper interfaces between adjacent β-sheets.

Chaperones

Proteins that assist in the folding, unfolding, assembly or disassembly of other macromolecular structures.

Protofilament

A structural component of an amyloid fibril with a cross-β structure that twists together with one or more additional protofibrils to form a mature amyloid fibril.

Subunits

The smallest units that make up an amyloid fibril, generally single copies of the precursor protein.

Amyloidoses

A class of diseases associated with the formation of amyloid fibrils, tangles and plaques, although the causative agents of disease have yet to be determined definitively.

Prion

A class of infectious amyloid fibrils.

Age of onset

The age at which a patient first presents symptoms. For amyloid-associated disorders, this is not necessarily directly correlated with fibril load: high fibril loads may be asymptomatic, whereas low fibril loads may lead to severe symptoms.

Haemodialysis

A dialysis-based filtration treatment that acts to replace kidney function in patients experiencing kidney failure.

Phase separation

A process driven by liquid–liquid demixing, leading to a liquid mixture separating into individual components. In cells, this can lead to localized increased concentration and supersaturation of biological molecules.

Intrinsically disordered proteins

Proteins that lack a fixed or ordered 3D structure.

Fibril load

A measure of the total amount of amyloid fibril within a sample or patient.

Native protein

The properly assembled form of a protein required for functionality.

Crossover

The distance it takes a fibril to achieve 180° of rotation. Crossover appears as the distance between the two narrowest points on a 2D EM or atomic force microscopy image of a twisted fibril.

Long-term potentiation

A persistent increase in synaptic strength after stimulation of the synapse.

Pi-stacking interactions

Attractive, noncovalent interactions between aromatic rings (phenylalanine, Tyr and Trp in proteins).

Biofilm

A group of microorganisms that have adhered to each other and/or a surface.

Gram-positive organisms

Bacteria that possess a peptidoglycan-containing cell wall, which can be positively stained with crystal violet dye, known as Gram stain.

Polymorphism

The same protein can assemble into amyloid fibrils that have different arrangements of subunits in the fibril, numbers of protofilaments, widths and/or crossover distances.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41580-018-0060-8